MX2011008243A - Derivados y medicina de aminopirazina. - Google Patents

Derivados y medicina de aminopirazina.

Info

Publication number
MX2011008243A
MX2011008243A MX2011008243A MX2011008243A MX2011008243A MX 2011008243 A MX2011008243 A MX 2011008243A MX 2011008243 A MX2011008243 A MX 2011008243A MX 2011008243 A MX2011008243 A MX 2011008243A MX 2011008243 A MX2011008243 A MX 2011008243A
Authority
MX
Mexico
Prior art keywords
alkyl
medicine
amino
halogen atom
aminopyrazine derivative
Prior art date
Application number
MX2011008243A
Other languages
English (en)
Inventor
Tetsuo Asaki
Hidetaka Fujihara
Katsutoshi Hori
Haruna Naito
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of MX2011008243A publication Critical patent/MX2011008243A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Un compuesto representado por la fórmula general [1] que satisface los siguientes (I) o (II), o una sal farmacéuticamente aceptable del compuesto. (I) X e CH o N; R' es un átomo de halógeno; y R2 es H, un átomo de halógeno, CN, [2], [3], [8], [9] , un O--alquilo, un -O- (anillo saturado) etc. [2]: -C(RC) (RD) (RE) {RC a RE cada uno es H, un alquilo, etc.} [3]: N(RF)(RG){RF y RG cada uno es H, OH, amino, un (hetero)arilo, etc.}[8]: -C(=O)RL {RL es un alquilo, OH, un alcoxi, amino, etc. } [9] : un fenilo (substituido); (II) X es >C-C(=O)RB {RB es un amino (substituido), un alcoxi, OH, etc.}; R' es un átomo de halógeno; R2 es H; R3 es H u OH; y R3 y R4 cada uno es H o un alquilo.
MX2011008243A 2009-02-06 2010-02-05 Derivados y medicina de aminopirazina. MX2011008243A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009026470 2009-02-06
JP2009276133 2009-12-04
PCT/JP2010/051722 WO2010090290A1 (ja) 2009-02-06 2010-02-05 アミノピラジン誘導体及び医薬

Publications (1)

Publication Number Publication Date
MX2011008243A true MX2011008243A (es) 2011-08-17

Family

ID=42542181

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008243A MX2011008243A (es) 2009-02-06 2010-02-05 Derivados y medicina de aminopirazina.

Country Status (19)

Country Link
US (2) US8673891B2 (es)
EP (1) EP2394999B1 (es)
JP (1) JP5263304B2 (es)
KR (1) KR101677778B1 (es)
CN (1) CN102307869B (es)
AU (1) AU2010211672B2 (es)
BR (1) BRPI1008661B8 (es)
CA (1) CA2751695C (es)
DK (1) DK2394999T3 (es)
ES (1) ES2453474T3 (es)
HR (1) HRP20140265T1 (es)
MX (1) MX2011008243A (es)
MY (1) MY155374A (es)
PL (1) PL2394999T3 (es)
PT (1) PT2394999E (es)
RU (1) RU2535217C2 (es)
SI (1) SI2394999T1 (es)
WO (1) WO2010090290A1 (es)
ZA (1) ZA201105623B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11680055B2 (en) 2017-09-28 2023-06-20 Nippon Shinyaku Co., Ltd. Crystals

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2394999B1 (en) * 2009-02-06 2014-01-29 Nippon Shinyaku Co., Ltd. Aminopyrazine derivative and medicine
US20120121515A1 (en) 2009-03-13 2012-05-17 Lenny Dang Methods and compositions for cell-proliferation-related disorders
ES2632954T3 (es) 2009-06-29 2017-09-18 Agios Pharmaceuticals, Inc. Derivados de quinolina-8-sulfonamida que tienen una actividad anticancerosa
WO2011050210A1 (en) 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
WO2012005299A1 (ja) * 2010-07-07 2012-01-12 日本新薬株式会社 Ｒｏｓチロシンキナーゼ阻害剤
JP5668756B2 (ja) * 2010-08-11 2015-02-12 日本新薬株式会社 悪性リンパ腫治療剤
WO2012020786A1 (ja) * 2010-08-11 2012-02-16 日本新薬株式会社 医薬組成物
EP2702055A1 (en) * 2011-04-11 2014-03-05 Nerviano Medical Sciences S.r.l. Pyrazolyl-pyrimidine derivatives as kinase inhibitors
SG194697A1 (en) 2011-05-03 2013-12-30 Agios Pharmaceuticals Inc Pyruvate kinase activators for use in therapy
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
WO2013004332A1 (en) * 2011-07-07 2013-01-10 Merck Patent Gmbh Substituted azaheterocycles for the treatment of cancer
EP2554544A1 (en) * 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
AU2012313888B2 (en) * 2011-09-27 2016-03-31 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
CN115536635A (zh) 2012-01-06 2022-12-30 法国施维雅药厂 治疗活性化合物及其使用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
EP2832734A4 (en) 2012-03-28 2015-08-26 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
EP2906212A4 (en) 2012-10-15 2016-06-08 Agios Pharmaceuticals Inc THERAPEUTIC COMPOUNDS AND COMPOSITIONS
WO2014060381A1 (de) 2012-10-18 2014-04-24 Bayer Cropscience Ag Heterocyclische verbindungen als schädlingsbekämpfungsmittel
EP2914587A1 (de) 2012-10-31 2015-09-09 Bayer CropScience AG Neue heterocylische verbindungen als schädlingsbekämpfungsmittel
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
US9834520B2 (en) 2013-03-14 2017-12-05 Takeda Pharmaceutical Company Limited Heterocyclic compound
AP2015008707A0 (en) 2013-03-14 2015-09-30 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
US20160039802A1 (en) * 2013-03-14 2016-02-11 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2014147586A1 (en) * 2013-03-22 2014-09-25 Novartis Ag 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
JP6427491B2 (ja) 2013-07-03 2018-11-21 武田薬品工業株式会社 複素環化合物
ES2950424T3 (es) 2013-07-03 2023-10-09 Takeda Pharmaceuticals Co Compuesto de amida
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3019480B1 (en) 2013-07-11 2020-05-06 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105492435B (zh) 2013-07-11 2018-06-29 安吉奥斯医药品有限公司 作为idh2突变体抑制剂的化合物
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US20160159773A1 (en) 2013-07-30 2016-06-09 Takeda Pharmaceutical Company Limited Heterocyclic compound
AU2014334040A1 (en) 2013-10-07 2016-04-28 Bayer Pharma Aktiengesellschaft Cyclic thienouracil-carboxamides and use thereof
KR20240010105A (ko) 2014-03-14 2024-01-23 아지오스 파마슈티컬스 아이엔씨. 치료적으로 활성인 화합물의 약제학적 조성물
WO2016024231A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor
PL3179991T3 (pl) 2014-08-11 2022-02-14 Acerta Pharma B.V. Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
JP2017214291A (ja) * 2014-10-09 2017-12-07 国立大学法人 宮崎大学 骨髄線維化の抑制剤
EP3307702A4 (en) * 2015-06-11 2019-02-13 University of Pittsburgh - Of the Commonwealth System of Higher Education CHEMICAL P62 ZZ HEMMER
US11234976B2 (en) 2015-06-11 2022-02-01 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
US10653710B2 (en) 2015-10-15 2020-05-19 Agios Pharmaceuticals, Inc. Combination therapy for treating malignancies
CA3216701A1 (en) 2015-10-15 2017-04-20 Les Laboratoires Servier Combination therapy for treating malignancies
WO2018005533A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
WO2020256739A1 (en) 2019-06-21 2020-12-24 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
WO2021091535A1 (en) 2019-11-05 2021-05-14 Constellation Pharmaceuticals, Inc. Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor
WO2020257644A1 (en) 2019-06-21 2020-12-24 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
WO2023175932A1 (ja) * 2022-03-18 2023-09-21 日本新薬株式会社 高リスク骨髄線維症の治療剤

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
WO2000071536A1 (en) * 1999-05-20 2000-11-30 E.I. Du Pont De Nemours And Company Heteroaryloxypyrimidine insecticides and acaricides
DE60006541D1 (de) * 1999-06-30 2003-12-18 Merck & Co Inc Src-kinase hemmende verbindungen
WO2001062900A1 (en) * 2000-02-25 2001-08-30 The Regents Of The University Of California. Scytonemin and methods of using thereof
AU2003284399A1 (en) * 2002-11-14 2004-06-03 Kyowa Hakko Kogyo Co., Ltd. Plk inhibitors
WO2005049602A1 (en) 2003-11-18 2005-06-02 Warner-Lambert Company Llc Quinolone antibacterial agents
GB0512324D0 (en) * 2005-06-16 2005-07-27 Novartis Ag Organic compounds
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
CN101273039A (zh) 2005-08-12 2008-09-24 默克公司 可用作p38激酶抑制剂的杂二环化合物
WO2007140200A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2009017838A2 (en) * 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
CA2720946C (en) * 2008-04-07 2013-05-28 Irm Llc Compounds and compositions as protein kinase inhibitors
EP2394999B1 (en) * 2009-02-06 2014-01-29 Nippon Shinyaku Co., Ltd. Aminopyrazine derivative and medicine

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11680055B2 (en) 2017-09-28 2023-06-20 Nippon Shinyaku Co., Ltd. Crystals

Also Published As

Publication number Publication date
EP2394999A1 (en) 2011-12-14
BRPI1008661B1 (pt) 2020-09-15
SI2394999T1 (sl) 2014-05-30
ZA201105623B (en) 2012-07-25
WO2010090290A1 (ja) 2010-08-12
EP2394999B1 (en) 2014-01-29
JPWO2010090290A1 (ja) 2012-08-09
AU2010211672B2 (en) 2016-08-04
CA2751695C (en) 2017-11-28
ES2453474T3 (es) 2014-04-07
US8586591B2 (en) 2013-11-19
CN102307869A (zh) 2012-01-04
BRPI1008661B8 (pt) 2021-05-25
MY155374A (en) 2015-10-15
BRPI1008661A2 (pt) 2016-03-08
RU2011136825A (ru) 2013-03-20
HRP20140265T1 (hr) 2014-04-25
CN102307869B (zh) 2014-10-22
US8673891B2 (en) 2014-03-18
US20130131082A1 (en) 2013-05-23
AU2010211672A1 (en) 2011-08-25
KR101677778B1 (ko) 2016-11-18
EP2394999A4 (en) 2012-10-10
JP5263304B2 (ja) 2013-08-14
DK2394999T3 (da) 2014-05-05
PL2394999T3 (pl) 2014-06-30
PT2394999E (pt) 2014-05-02
RU2535217C2 (ru) 2014-12-10
KR20110120932A (ko) 2011-11-04
CA2751695A1 (en) 2010-08-12
US20110288065A1 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
MX2011008243A (es) Derivados y medicina de aminopirazina.
HRP20080429T3 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
RS53569B1 (en) NEW COMPOUNDS AND COMPOSITIONS, AND PROCEDURES FOR USE
PH12015501878A1 (en) Tetrahydroimidazo[1,5-d][1,4]oxazepine derivative
EA200870336A1 (ru) Полициклические производные циннамида
PH12014501804A1 (en) Cycloalkane derivative
NZ627036A (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
WO2009156861A3 (en) Substituted pyrimidone derivatives
MY177250A (en) Novel nicotinamide derivative or salt thereof
RS53688B1 (en) 1,2,5-OXADIAZOLES AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS
NZ592284A (en) Pyrrolobenzodiazepines
TW200745034A (en) New compounds
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
MX2010008686A (es) Derivado de pirrolopirimidina como inhibidor de fosfatidilinositol 3-quinasa y uso del mismo.
MY139887A (en) Tetrahydronaphthyridine derivatives and a process for preparing the same.
RS51545B (en) THIAZOL PIRAZOLOPIRAMIDINS AS ANTAGONISTS OF CRF1 RECEPTORS
WO2008136444A1 (ja) 縮合複素環誘導体
TN2011000422A1 (en) Benzofuran derivatives
MX344529B (es) Derivados antibioticos de 2 - oxo -oxazolidin - 3, 5 -diilo.
MX2009003927A (es) Derivado espirocetal de tioglucosa y uso del mismo como un agente terapeutico para la diabetes.
MY183861A (en) Pyrazolopyrimidine derivative
JO3143B1 (ar) مركبات تتراهيدرو بيرولو ثيازين
MX2022015330A (es) N-fenilaminocarbonil piridino-, pirimidino y benzo-tropanos como moduladores de gpr65.
MY143665A (en) Method of producing aminophenol compounds.
TW200602320A (en) Indol compounds

Legal Events

Date Code Title Description
FG Grant or registration